Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer12


PURPOSE To improve the selection of advanced colorectal cancer patients to panitumumab by optimizing the assessment of RAS (KRAS-NRAS) mutations. EXPERIMENTAL DESIGN Using a centralized pyrosequencing RAS assay, we analyzed the tumors of 94 patients, wild-type for KRAS mutations (codons 12 to 13) by Sanger sequencing (SS), treated with panitumumab… (More)
DOI: 10.1016/j.neo.2014.08.002


5 Figures and Tables